HIV
Conditions
Brief summary
This is a multicenter, single arm, 48-week open-label study of FDC ELV/COBI/FTC/TDF \[Stribild\] in acute HIV infection. Study sites will be members of the Duke-UNC Acute HIV Infection Study Consortium. Participants will be enrolled for 96 weeks. Clinical care and study drug (ELV/COBI/FTC/TDF) will be provided for the first 48 weeks. After week 48, clinical care but not study drug will be provided through week 96. A study participant suppressed at week 48 can continue on FDC ELV/COBI/FTC/TDF. The primary hypothesis is that once daily fixed-dose combination elvitegravir (ELV), cobicistat (COBI), emtricitabine (FTC), and tenofovir disoproxil fumarate (TDF) will rapidly reduce viral replication to \<50 copies RNA/ml in participants with acute HIV infection. The secondary hypotheses to be considered are 1) virologic response rates as measured by plasma HIV RNA levels will be non-inferior or superior to a historical group of participants from the PHI cohort treated with EFV/FTC/TDF, 2) compared to historical controls treated with EFV/FTC/TDF, plasma HIV RNA will decrease more rapidly in PHI participants treated with ELV/COBI/FTC/TDF, 3) compared to historical controls treated with EFV/FTC/TDF, immune activation as measured by the proportion CD4+ and CD8+ cells expressing HLA-DR and CD38+ will decrease more rapidly in PHI participants treated with ELV/COBI/FTC/TDF, 4)in a subset of participants samples will be obtained from compartments such as the gastrointestinal tract, and lymphoid tissues to assess changes over time in parameters such as HIV-1 RNA, immunologic responses to HIV, and tissue and anatomic reservoirs. We hypothesize that treatment with the ELV/COBI/FTC/TDF will demonstrate improved viral clearance in these compartments as compared to historical controls treated with EFV/FTC/TDF. 5) in a subset of participants who remain suppressed on therapy, resting CD4 cells with replication-competent HIV-1 (latent reservoir) will be quantitated and compared to similar measurements in PHI participants treated with EFV/FTC/TDF. In addition, we will compare these results to those measured in HIV-1 infected participants treated and 6) ELV/COBI/FTC/TDF will be well tolerated, and the proportion of participants who require treatment modification will be less than that observed in participants treated with EFV/FTC/TDF.
Detailed description
None desired
Interventions
DRUG(FDC) ELV/COBI/FTC/TDF
Antiretroviral treatment
Sponsors
Duke University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
Acute HIV infection is defined as: 1. A positive 4th generation HIV Ag/Ab Combination Assay and HIV RNA (NAAT or viral load) and one of the following within 30 days of study entry: * a negative HIV rapid test * negative/indeterminate Western Blot OR 2. A negative or indeterminate HIV antibody, antigen, or nucleic acid amplification test (NAAT) and any one of the following within 30 days of study entry: * A detectable HIV nucleic acid in blood confirmed by a second NAAT * Positive p24 antigen * A positive HIV antibody test according to standard criteria obtained within 45 days after an initial negative or indeterminate HIV antibody, antigen, or nucleic acid amplification. Inclusion Criteria: 1. Acute HIV Infection (as defined above) within 30 days of study entry. 2. Age \>18 years. 3. ART-naive (\<14 days of previous antiretroviral treatment. Exceptions are: Post-exposure prophylaxis (PEP) if participant was documented as HIV-negative at least 3 months after completion of PEP. 4. Lab values within 30 days prior to study entry: 1. Absolute neutrophil count \>500/mm3 2. Hemoglobin \> 8.5 g/dL for men and \> 8.0 g/dL for women 3. Platelet count \>50,000/mm3 4. AST (SGOT)\> .2.5 x ULN 5. ALT (SGPT)\> .2.5 x ULN 6. Total bilirubin \<2.5 x ULN 7. Calculated creatinine clearance (Cockcroft-Gault formula) \> 70mL/min: 5. For women of reproductive potential, a negative pregnancy test within 72 hours prior to initiating antiretroviral study medications. Reproductive potential is defined as females who have reached menarche and have not been post-menopausal for at least 24 consecutive months, or have not undergone surgical sterilization. 6. Female study participants must use a reliable form of barrier contraception, such as a condom, even if they also use other methods of birth control. All participants must continue to use contraception for 12 weeks after stopping study medications. Acceptable methods of barrier contraception include: condoms (male or female), diaphragm, or cervical cap. These can be used alone or in tandem with hormonal or IUD method. 7. Ability and willingness of participant to give written informed consent.
Exclusion criteria
1. Women who are pregnant or breast-feeding. 2. Women with a positive pregnancy test prior to study drug administration. 3. Men who have sex with women, and women of reproductive potential unwilling or unable to use an acceptable, reliable barrier method of contraception for the entire study period and 12 weeks afterwards. 4. Use of immunomodulators (e.g., interleukins, interferons, cyclosporine), HIV vaccine, systemic cytotoxic chemotherapy, or investigational therapy within 30 days of study entry (Prednisone 10 mg QD or less is permitted. 5. Known allergy/sensitivity to study drugs 6. Difficulty swallowing pills 7. Inability to communicate effectively with study personnel 8. Incarceration; prisoner recruitment and participation are not permitted 9. Active drug or alcohol use that, in the opinion of the site investigator, would interfere with participation in the study 10. Any active psychiatric illness that, in the opinion of the investigator, could confound the analysis of the neurological examination or neuropsychological test results 11. Active brain infection (except for HIV-1), brain neoplasm, space-occupying brain lesion requiring acute or chronic therapy 12. Serious illness requiring systemic treatment and/or hospitalization until patient either completes therapy or is clinically stable on therapy for at least 7 days prior to study entry 13. Known cardiac conduction disease 14. Prior treatment with any other experimental drug within 30 days of initiating study treatment 15. Unable to discontinue any current medications that are excluded during study treatment 16. Life expectancy less than twelve months 17. Acute Viral Hepatitis, including, but not limited to, Hepatitis A, B, or C 18. Chronic Hepatitis B Infection documented by a detectable serum Hepatitis B surface antigen (HBsAg) or plasma HBV DNA 19. Calculated creatinine clearance (Cockcroft-Gault formula) \<70mL/min
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of Participants With a Viral Load Measurement of <200 Copies/mL at Week 24 | 24 weeks |
| Virologic Efficacy of the Fixed Dose Combination (FDC) ELV/COBI/FTC/TDF Given Once Daily to Participants With Acute HIV Infection as Determined by the Proportion of Treated Participants With HIV-1 RNA to <50 Copies/mL at Week 48 | 48 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Immune Activation as Measured by the Proportion of CD4+ and CD8+ Cells Expressing HLA-DR and CD38+ | 48 weeks |
| Rate of Virologic Decline in the First 48 Weeks of Treatment Comparing FDC ELV/COBI/FTC/TDF to FDC EFV/FTC/TDF | 48 weeks |
Other
| Measure | Time frame |
|---|---|
| Number of Participants With Grade 3 or Grade 4 Adverse Events | 48 weeks |
| Number of Participants With Adverse Events Related to Study Drug | 48 weeks |
Countries
United States
Participant flow
Recruitment details
Participants for this study are recruited from AHI participants referred to our ID clinics. Referrals are generated from the NC STAT Program and from clinical diagnoses made by both internal and external health care clinics.
Participants by arm
| Arm | Count |
|---|---|
| Quad FDC FDC elvitegravir + cobicistat + tenofovir + emtricitabine STR once daily for 48 weeks
(FDC) ELV/COBI/FTC/TDF: Antiretroviral treatment | 33 |
| Total | 33 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Lost to Follow-up | 3 |
Baseline characteristics
| Characteristic | Quad FDC |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 0 Participants |
| Age, Categorical Between 18 and 65 years | 33 Participants |
| Sex: Female, Male Female | 6 Participants |
| Sex: Female, Male Male | 27 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 22 / 33 |
| serious Total, serious adverse events | 0 / 33 |
Outcome results
Primary
Number of Participants With a Viral Load Measurement of <200 Copies/mL at Week 24
Time frame: 24 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Quad FDC | Number of Participants With a Viral Load Measurement of <200 Copies/mL at Week 24 | 28 participants |
Primary
Virologic Efficacy of the Fixed Dose Combination (FDC) ELV/COBI/FTC/TDF Given Once Daily to Participants With Acute HIV Infection as Determined by the Proportion of Treated Participants With HIV-1 RNA to <50 Copies/mL at Week 48
Time frame: 48 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Quad FDC | Virologic Efficacy of the Fixed Dose Combination (FDC) ELV/COBI/FTC/TDF Given Once Daily to Participants With Acute HIV Infection as Determined by the Proportion of Treated Participants With HIV-1 RNA to <50 Copies/mL at Week 48 | 24 participants |
Secondary
Immune Activation as Measured by the Proportion of CD4+ and CD8+ Cells Expressing HLA-DR and CD38+
Time frame: 48 weeks
Population: Data not collected
Secondary
Rate of Virologic Decline in the First 48 Weeks of Treatment Comparing FDC ELV/COBI/FTC/TDF to FDC EFV/FTC/TDF
Time frame: 48 weeks
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Quad FDC | Rate of Virologic Decline in the First 48 Weeks of Treatment Comparing FDC ELV/COBI/FTC/TDF to FDC EFV/FTC/TDF | HIV RNA <200 copies/mL | 26 days |
| Quad FDC | Rate of Virologic Decline in the First 48 Weeks of Treatment Comparing FDC ELV/COBI/FTC/TDF to FDC EFV/FTC/TDF | HIV RNA <50 copies/mL | 54 days |
p-value: <0.001Wilcoxon (Mann-Whitney)
Other Pre-specified
Number of Participants With Adverse Events Related to Study Drug
Time frame: 48 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Quad FDC | Number of Participants With Adverse Events Related to Study Drug | 22 participants |
Other Pre-specified
Number of Participants With Grade 3 or Grade 4 Adverse Events
Time frame: 48 weeks
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Quad FDC | Number of Participants With Grade 3 or Grade 4 Adverse Events | Grade 3 | 3 participants |
| Quad FDC | Number of Participants With Grade 3 or Grade 4 Adverse Events | Grade 4 | 0 participants |